E. E. Voest, MD, PhD; G. Vreugdenhil, MD, PhD; J. J. M. Marx, MD, PhD
Voest EE, Vreugdenhil G, Marx JJM. Iron-Chelating Agents in Non-Iron Overload Conditions. Ann Intern Med. 1994;120:490-499. doi: 10.7326/0003-4819-120-6-199403150-00008
Download citation file:
Published: Ann Intern Med. 1994;120(6):490-499.
To review the current clinical experience with iron chelators in non-iron overload conditions.
The English-language literature was searched from 1983 through 1992 manually and using MEDLINE.
Original articles, case reports, and abstracts addressing iron chelation.
Selected reports that described clinical applications of iron chelators in non-iron overload conditions were classified according to their stated mechanism of interference with disease activity. Articles stating the rationale for clinical use of iron chelators were also included.
Iron chelators were used in non-iron overload conditions to produce antioxidant effects, antiproliferative effects, and antiprotozoal effects and for aluminum chelation. In addition, several reports described singular observations in various diseases. Deferoxamine is the only iron chelator available for clinical studies. The treatment-related (side) effects appear to be associated with patient iron levels.
Randomized clinical trials are needed to confirm the promising effects of iron chelators in non-iron overload conditions. Oral iron chelators with fewer toxic effects are especially needed.
Learn more about subscription options.
Register Now for a free account.
Autoimmune Kidney Disease, Emergency Medicine, Hematology/Oncology, Nephrology, Pulmonary/Critical Care.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only